What is Abel Screening?
Abel Screening operates at the intersection of healthcare technology and clinical diagnostics, providing essential interpretive services for ASI test reports. By offering direct access to expert clinicians via telephone consultations, the company bridges the gap between raw diagnostic data and actionable patient insights. This service-oriented model is bolstered by a robust technical support infrastructure, ensuring that healthcare providers receive comprehensive assistance throughout the diagnostic process. The company's focus on accessibility and professional guidance positions it as a critical partner for clinicians navigating complex screening protocols, effectively enhancing the utility of diagnostic outputs through a value-added, no-cost support framework.
How much funding has Abel Screening raised?
Abel Screening has raised a total of $126K across 1 funding round:
Debt
$126K
Debt (2021): $126K with participation from PPP
Key Investors in Abel Screening
PPP
Public-Private Partnership
What's next for Abel Screening?
With the recent influx of capital, Abel Screening is well-positioned to scale its clinical support operations and enhance its digital diagnostic infrastructure. The company is expected to leverage this financing to broaden its reach within the healthcare sector, potentially integrating more advanced analytical tools into its existing consultation framework. As the firm transitions through this late-stage growth phase, the focus will likely shift toward optimizing service delivery efficiency and expanding the scope of its clinical advisory network. By maintaining its commitment to high-quality, expert-led support, Abel Screening aims to further entrench its role as a vital component of the modern diagnostic ecosystem, ensuring that clinicians remain equipped with the necessary expertise to interpret complex data accurately.
See full Abel Screening company page
